Skip to main content

Table 2 Study objectives

From: INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer

Primary objective To assess the treatment effect of L-BLP25 plus BSC, as compared to BSC alone, on overall survival time
Secondary objectives Time to symptom progression (based on LCSS questionnaire)
  Time to progression
  Progression-free survival time
  Time to treatment failure
  Safety
Other objectives Quality-of-life (EQ-5D/LCSS)
  Healthcare resource utilization and work status
  Biomarkers/pharmacogenetics
  1. BSC: best supportive care; EQ-5D: EuroQol Group 5-Dimension questionnaire; LCSS: Lung Cancer Symptom Scale.